XTAI
1733
Market cap95mUSD
Oct 08, Last price
30.45TWD
1D
-0.33%
1Q
0.50%
Jan 2017
-26.27%
IPO
51.49%
Name
Apex Biotechnology Corp
Chart & performance
P/E
18.67
P/S
1.56
EPS
1.63
Div yield, %
3.94%
Shrs. gr., 5y
-2.41%
Rev. gr., 5y
-0.61%
Revenues
1.94b
+5.00%
Net income
163m
+27.38%
CFO
164m
-50.06%
Dividend
Jun 09, 20261.3 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Apex Biotechnology Corp. is a Taiwanese firm that specializes in the global development, manufacturing, and distribution of medical devices designed for home use, all powered by sophisticated biosensor technology. Their comprehensive product lineup features a variety of personal health monitoring systems, including those for tracking blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1c, and ketone levels. In addition, the company provides self-testing solutions for coagulation and multi-parameter analysis, alongside advanced hemoglobin screening systems. Beyond patient diagnostics, Apex Biotech also offers systems for detecting pesticide residues. The company further extends its services to include digital care management and telehealth platforms. Established in 1997, Apex Biotechnology Corp. operates from its headquarters located in Hsinchu City, Taiwan.
Key people
Yingxiang Zhu
Chief Financial Officer-Finance Division · since 1999
Yanshi Shen
Chairman of the Board, General Manager · since 1997
Chengyu Shen
Deputy General Manager-Business Division · since 2016
Chunhui Wu
Deputy General Manager-Management Division · since 1997
Renhao Tian
Director · since 2024
Mengwen Yang
Deputy General Manager-Manufacturing Division, Director · since 2006
Zhengming Bai
Independent Director · since 2018
Jinchang Bao
Independent Director · since 2018
Independent Director · since 2021
Zhenyi Wu
Independent Director · since 2024
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||